CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Vigiis 101-LAB +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04046432
NCT04046432N/ACompleted
CompareCT.gov

Effects of Vigiis 101-LAB on Gut Health

SunWay Biotech Co., LTD.·interventional·Posted Aug 6, 2019·Updated Aug 7, 2019

In Brief

A clinical study evaluating Vigiis 101-LAB and Placebo for Gastrointestinal Microbiome. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Vigiis 101-LAB capsules I and II are produced from the fermentation of Lactobacillus paracasei subsp. paracasei NTU 101. Investigators have examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day, respectively) on gut microflora in clinical trial 1, and on peristalsis, related immunity, and anti-oxidative capacity in clinical trial 2, during a 4-week randomized, double-blind, placebo-controlled, adaptive-design study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Microbiome
CountriesTaiwan
CollaboratorsNational Taiwan University Hospital, Chung Shan Medical University

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 6, 2019
Enrollment StartMar 27, 2017
Primary CompletionDec 22, 2017
Study CompletionMar 20, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.9 years ago

Interventions

Vigiis 101-LABdietary

examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)

Placebodietary

Maltodextrin was used as a placebo.